• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Quality and Operations Foster Karen A. sold $5,751 worth of shares (286 units at $20.11), decreasing direct ownership by 0.15% to 195,567 units (SEC Form 4)

    4/11/25 5:49:02 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BLFS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Foster Karen A.

    (Last) (First) (Middle)
    3303 MONTE VILLA PARKWAY
    SUITE 310

    (Street)
    BOTHELL WA 98021

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIOLIFE SOLUTIONS INC [ BLFS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Quality and Operations
    3. Date of Earliest Transaction (Month/Day/Year)
    04/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/09/2025 S(1) 286 D $20.11 195,567 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
    Remarks:
    /s/ Karen A. Foster 04/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BLFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLFS

    DatePrice TargetRatingAnalyst
    9/30/2024$29.00Buy
    H.C. Wainwright
    4/4/2024$22.00Buy
    Jefferies
    7/11/2023$29.00Buy
    Craig Hallum
    4/25/2022$28.00Perform → Outperform
    Oppenheimer
    10/19/2021$61.00Buy
    B. Riley Securities
    10/15/2021$64.00Outperform
    Cowen
    8/13/2021$50.00 → $60.00Overweight
    Keybanc
    More analyst ratings

    $BLFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioLife Solutions Updates Earnings Call Information

      BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally. About BioLife Solutions BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our exper

      5/8/25 4:32:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports First Quarter 2025 Financial Results

      Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

      5/8/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati

      4/30/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BLFS
    Leadership Updates

    Live Leadership Updates

    See more
    • BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

      BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an

      3/18/25 8:30:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

      Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.

      8/25/22 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BLFS
    Financials

    Live finance-specific insights

    See more
    • BioLife Solutions Reports First Quarter 2025 Financial Results

      Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

      5/8/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati

      4/30/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

      Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens BioLife's position a

      4/7/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BLFS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BLFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BLFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BLFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Casdin Partners Master Fund, L.P. bought $10,374,976 worth of shares (927,165 units at $11.19) (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      10/23/23 5:42:32 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 4 filed by Large owner Casdin Partners Master Fund, L.P.

      4/A - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/29/25 9:57:30 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Wichterman Troy sold $18,743 worth of shares (932 units at $20.11), decreasing direct ownership by 0.49% to 188,310 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:43 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EVP & Chief Scientific Officer Mathew Aby J. sold $11,443 worth of shares (569 units at $20.11), decreasing direct ownership by 0.18% to 309,007 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:33 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      2/13/24 5:00:45 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      1/24/24 4:16:40 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by BioLife Solutions Inc. (Amendment)

      SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      10/24/23 4:29:23 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • H.C. Wainwright initiated coverage on BioLife Solutions with a new price target

      H.C. Wainwright initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

      9/30/24 7:39:39 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on BioLife Solutions with a new price target

      Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00

      4/4/24 7:31:02 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Craig Hallum initiated coverage on BioLife Solutions with a new price target

      Craig Hallum initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

      7/11/23 8:52:08 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BLFS
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioLife Solutions Inc.

      10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      5/8/25 4:20:40 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      5/8/25 4:10:31 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.

      10-K/A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      4/8/25 4:34:04 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care